This trial is active, not recruiting.

Conditions schwannoma, vestibular, neurofibromatosis 2, meningioma
Sponsor House Ear Institute
Start date January 2002
Trial size 100 participants
Trial identifier NCT00004483, 199/14226, HEI-DAMD17-01-1-0710, HEI-NF2



I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model natural history
Time perspective longitudinal

Eligibility Criteria

Male or female participants at least 5 years old.

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosed with neurofibromatosis 2 on or after 01/01/93 - Must meet one of the following conditions: Bilateral vestibular schwannoma OR Family history of neurofibromatosis 2 (first degree family relative) AND Unilateral vestibular schwannoma at under 30 years OR Any 2 of the following: Meningioma Glioma Schwannoma Juvenile posterior subcapsular lenticular opacity/juvenile cortical cataract - No plans to treat vestibular schwannoma in next 12 months --Prior/Concurrent Therapy-- - Not specified --Patient Characteristics-- - Age: 5 and over

Additional Information

Description PROTOCOL OUTLINE: Data on the clinical course and growth rate of NF2-related tumors in patients with neurofibromatosis 2. Patients are evaluated each year on a cranial and a spinal MRI, eye tests, hearing tests, quality of life, neurological tests, and physical functioning.
Trial information was received from ClinicalTrials.gov and was last updated in September 2005.
Information provided to ClinicalTrials.gov by Office of Rare Diseases (ORD).